This post was originally published on this site The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut down a gene involved in B-Cell non-Hodgkin’s lymphoma, and understand who is at risk of developing a…
This post was originally published on this site Exposure to glyphosate, a common broad-spectrum herbicide used worldwide, increases the risk of non-Hodgkin’s lymphoma (NHL) by 41 percent in humans, a study says. The study, “Exposure to Glyphosate-Based Herbicides and Risk for Non-Hodgkin Lymphoma: A Meta-Analysis and Supporting Evidence,” were published in Mutation Research/Reviews in Mutation…
This post was originally published on this site I-Mab Biopharma is planning the first-in-human U.S. clinical study evaluating the safety, tolerability, and efficacy of its investigational candidate TJC4 as a treatment for solid tumors and lymphoma. The Phase 1/1b trial will explore TJC4 alone and in combination with other therapies, and is expected to launch…
This post was originally published on this site A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imfinzi (durvalumab) in multiple types of advanced non-Hodgkin’s lymphoma has dosed the first patient. The study (NCT03685344) is for adults with advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL) who have relapsed or…
This post was originally published on this site Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. The study, “Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma,” was published in…
This post was originally published on this site U.S. regulators have granted orphan drug status to TP Therapeutics’ TPX-0005 as a treatment for non-small cell lung cancers with certain gene mutations, according to a company press release. The Federation Drug Administration decision is aimed at accelerating TPX-0005’s approval. The designation will also give the company seven years of…
This post was originally published on this site Patients with an aggressive kind of skin cancer called Merkel cell carcinoma appear to have better responses and live longer when given the PD-1 inhibitor Keytruda (pembrolizumab), compared to previous patients given first-line chemotherapy, a Phase 2 clinical trial shows. The findings support Keytruda’s recent accelerated approval for…
This post was originally published on this site The U.S. Food and Drug Administration has granted priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) in combination with Inlyta (axitinib) for the initial treatment of advanced renal cell carcinoma (RCC) patients, with a final decision expected June 20, the company announced. The application…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) in combination with chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC) patients. The CHMP’s opinion was based on clinical evidence from the KEYNOTE-407 Phase…
This post was originally published on this site Merck KGaA and GlaxoSmithKline (GSK) are working together to develop and commercialize the immunotherapy candidate M7824 (bintrafusp alfa) as a potential treatment for multiple, difficult-to-treat types of cancer. M7824 is being developed by Merck KGaA, which operates as by EMD Serono in the U.S. and Canada, and will…
